Elder Projects Peer Comparison

BSE: 524788

₹20.15

₹0.00 (0.00%)

As on 03-Dec-2015IST

Market cap

₹7 Cr

Revenue (TTM)

₹2 Cr

P/E Ratio

--

P/B Ratio

-1.4

Div. Yield

0 %

Edit

	Elder Projects	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	7	37,857	27,713	26,763	28,045
Revenue (₹ Cr)	2	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	-2.98	414.00	288.22	387.35	-371.81
Net Margin (%)	-73.29	11.23	14.79	26.01	-3.93
RoE (%)	--	8.38	29.77	25.18	-3.85
Price to Earnings	--	92.56	96.15	69.30	--
Price-To-Book	-1.44	7.52	20.65	15.51	3.50

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Elder Projects	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	9.77	4,350.50	34.80	33.90	--
Total Income	11.11	4,375.84	34.80	34.61	--
Total Expenditure	7.38	2,996.79	25.65	30.42	--
EBITDA	2.39	1,353.71	9.15	3.48	--
Depreciation	0.60	115.07	2.71	1.05	--
EBIT	1.79	1,238.64	6.44	2.42	--
Interest	2.83	269.02	2.51	1.10	--
Other Income	1.34	25.34	0.42	0.71	--
Exceptional Items	--	-473.77	--	--	--
Profit before Tax	0.30	521.19	3.93	2.03	--
Provision for Tax	0.24	221.74	1.40	0.68	--
Profit after Tax	0.06	299.45	2.52	1.35	--

Liabilities (₹ Cr)

	Elder Projects	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	1.96	1,471.02	37.49	6.11	--
Minority Interest	--	--	--	--	--
Non-Current Liabilities	-0.74	2,891.88	5.39	0.04	--
Current Liabilities	22.51	1,890.94	24.92	15.82	--
Total Liabilities	24.72	6,253.84	67.79	22.09	--

Assets (₹ Cr)

	Elder Projects	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	19.40	3,772.33	47.64	5.51	--
Current Assets	4.28	2,481.51	20.15	16.45	--
Total Assets	24.72	6,253.84	67.79	22.09	--
Total Debt*	20.96	3,492.50	19.14	6.41	--
Net Current Assets	-18.23	590.57	-4.76	0.63	--
Contingent Liabilities	0.10	46.91	0.71	--	--

Cashflow (₹ Cr)

	Elder Projects	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	2.95	1,343.83	5.07	--	--
Cash Flow from Investing Activities	-1.08	-305.45	-4.60	--	--
Cash from Financing Activities	-1.75	-826.56	-0.83	--	--
Net Cash Inflow / Outflow	0.12	211.82	-0.36	0.00	--

Ratios

Profitability Ratios

	Elder Projects	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	14.41	16.20	12.09	25.61	--
ROE (%)	2.97	66.74	14.65	24.87	--
ROA (%)	0.25	4.97	4.06	6.42	--
EBIT Margin (%)	38.18	31.70	26.29	12.34	--
Net Margin (%)	0.50	6.84	7.25	3.90	--
Cash Profit Margin (%)	6.74	9.52	15.04	6.56	--

Growth Ratios

	Elder Projects	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	11.63	15.97	65.29	21.86	--
EBIT Growth (%)	29.33	29.05	42.04	27.63	--
Net Profit Growth (%)	428.99	212.90	6.25	7.55	--
EPS Growth (%)	428.82	278.36	6.25	7.55	--
Book Value Growth (%)	4.43	253.45	15.81	28.51	--

Valuation Ratios

	Elder Projects	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	0.00	17.64	0.00	0.00	--
Price / Book Value	0.00	9.37	0.00	0.00	--
Dividend Yield (%)	--	0.00	--	--	--
EV/EBITDA	6.40	7.33	4.36	1.71	--
Market Cap (₹ Cr)	0.00	6,555.46	0.00	0.00	--

Solvency Ratios

	Elder Projects	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	10.96	2.39	0.51	1.05	--
Short term debt to equity ratio	10.59	0.18	0.21	0.88	--
Current Ratio	0.19	1.31	0.81	1.04	--
Quick Ratio	0.17	0.84	0.77	0.66	--
Interest Coverage	1.11	2.94	2.57	2.86	--

Operating Efficiency Ratios

	Elder Projects	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	23.49	17.44	42.51	24.27	--
Asset Turnover	0.44	0.72	0.56	1.74	--
Receivable days	57.99	57.17	120.33	81.45	--
Inventory Days	19.63	67.16	9.04	45.36	--
Payable days	330.95	116.25	535.25	134.63	--
Cash Conversion Cycle	-253.33	8.07	-393.94	-7.82	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly